AnaptysBio's skin disease drug meets main goal in late-stage study
09/10/2023 13:05
Oct 9 (Reuters) - AnaptysBio Inc ANAB.O said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila) ((Khushi.Mandowara@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged